BioPharmSignal logoBioPharmSignal

Biotech News

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesFDA / regulatory

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response BOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing

Related news

ANGOAngioDynamics2026-06-17 12:30 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

ADPTAdaptive Biotechnologies2026-05-29 11:30 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ICCMIceCure Medical2026-07-29 12:25 EST

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

ICCMIceCure Medical2026-06-17 12:25 EST

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

PRCTPROCEPT BioRobotics2026-05-28 12:00 EST

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

AORTArtivion2026-06-29 11:00 EST

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

HYPRHyperfine2026-05-26 12:15 EST

Hyperfine to Join Russell 2000® and Russell 3000® Indexes

DCTHDelcath Systems2026-07-09 12:00 EST

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-15 20:10 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Stock data

Close
23.60 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States